Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples.

Authors:
Address: National Reference center for Hepatitis B and C in Blood Transfusion, Institut National de la Transfusion Sanguine, Paris, France. aservant@ints.fr
Journal:

Publication:

abstract

BACKGROUND:

Natural variation and mutations in the envelope protein (S) of hepatitis B virus can translate into HBsAg variants no longer detectable by conventional HBsAg assays.

OBJECTIVES:

The aim of the study was to assess the performance of 13 commercial assays currently used for screening and clinical analysis of HBsAg variants.

STUDY DESIGN:

The limit of detection (LOD) for each assay was established using two reference standards (WHO HBsAg 00/588 and the SFTS French reference). Sensitivity was evaluated using different panels. Panel 1 included 25 recombinant HBs variants at three concentrations, panels 2 and 4 included 8 recombinant HBsAg variants and 9 wild-type proteins (genotypes A-F), respectively, panel 3 included 16 natural HBsAg variants.

RESULTS:

LODs ranged from 0.011 to 0.095 IU/ml with the WHO standard, and from 0.021 to 0.326 ng/ml with the French reference. The overall percentage of positive signals using HBsAg variants ranged from 62.9% to 97.9%. Three substitutions: T123, D144A and G145, were negative at all concentrations with at least one assay.

DISCUSSION:

Our findings show that, although they fulfil CE requirements for analytical sensitivity (LODs below 0.13 IU/ml), HBsAg assays may vary in their capacity to detect HBsAg variants. This limit in diagnosis performance should encourage the health regulatory agencies to include HBsAg variant panels in the evaluation process.

Related Articles
Multi-center evaluation of the hepatitis B surface antigen (HBsAg) assay and HbsAg confirmatory assay for the family of Access immunoassay systems.
Clin Lab. 2010
Multi-center evaluation of the hepatitis B surface antigen (HBsAg) assay and HbsAg confirmatory assay for the family of Access immunoassay systems.
Lunel-Fabiani F, Duburcq X, Levayer T, Descamps F, Maniez-Montreuil M, Pivert A, Ducancelle A, Pouzet A, Marant L, Clèment A, et al. Clin Lab. 2010; 56(7-8):281-90.
Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen.
Transfus Med. 2010
Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen.
Zhang R, Wang L, Li J. Transfus Med. 2010 Oct; 20(5):322-8.
Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection.
J Med Virol. 2006
Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection.
Scheiblauer H, Soboll H, Nick S. J Med Virol. 2006; 78 Suppl 1:S66-70.
Review Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.
J Clin Virol. 2005
Review Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.
Weber B. J Clin Virol. 2005 Feb; 32(2):102-12.
Review New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.
Mol Diagn Ther. 2006
Review New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.
Kuhns MC, Busch MP. Mol Diagn Ther. 2006; 10(2):77-91.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.